Key result
The novel chemical scaffold F10, identified via AI-based virtual screening, acts as a cardiac-specific myosin inhibitor that reduces actomyosin ATPase activity by up to 89% and decreases left ventricular systolic pressure by 65% in isolated rat hearts.
Why the study?
Direct modulation of cardiac myosin function has emerged as a therapeutic target for heart disease and heart failure, but the development of myosin-based therapeutics has been hampered by the lack of targeted in vitro screening assays.
Does the novel small molecule F10 inhibit human β-cardiac myosin and reduce force and left ventricular pressure in preclinical models?
Does the novel small molecule F10 inhibit human β-cardiac myosin and reduce force and left ventricular pressure in preclinical models?
Effect estimate: 89% maximal decrease
AI-based virtual screening successfully identified F10, a novel cardiac-specific myosin inhibitor that reduces force and left ventricular pressure in preclinical models, providing a new scaffold for heart failure therapeutics.
Hypothesis-generating for myosin-targeted therapies; leaves open in vivo translation and clinical utility.
Direct modulation of cardiac myosin function has emerged as a therapeutic target for both heart disease and heart failure. However, the development of myosin-based therapeutics has been hampered by the lack of targeted in vitro screening assays. In this study we use Artificial Intelligence-based virtual high throughput screening (vHTS) to identify novel small molecule effectors of human β-cardiac myosin. We test the top scoring compounds from vHTS in biochemical counter-screens and identify a novel chemical scaffold called 'F10' as a cardiac-specific low-micromolar myosin inhibitor. Biochemical and biophysical characterization in both isolated proteins and muscle fibers show that F10 stabilizes both the biochemical (i.e. super-relaxed state) and structural (i.e. interacting heads motif) OFF state of cardiac myosin, and reduces force and left ventricular pressure development in isolated myofilaments and Langendorff-perfused hearts, respectively. F10 is a tunable scaffold for the further development of a novel class of myosin modulators.
No takes yet. Share an insight, caveat, or question.
Parijat et al. (2023) studied Heart disease and heart failure. F10 vs. Vehicle control (DMSO) was evaluated on Actomyosin ATPase activity (89% maximal decrease). The novel chemical scaffold F10, identified via AI-based virtual screening, acts as a cardiac-specific myosin inhibitor that reduces actomyosin ATPase activity by up to 89% and decreases left ventricular systolic pressure by 65% in isolated rat hearts.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: